Can 19-nortestosterone derivatives be aromatized in the liver of adult humans? Are there clinical implications?

Climacteric

Volumn 10, Issue 4, 2007, Pages 344-353

  Kuhl, H ^a   Wiegratz, I ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

19 Nortestosterone derivatives; 7 methyl ethinylestradiol; Aromatization; Clinical implications; Human liver; Tibolone

Indexed keywords

7ALPHA METHYL ETHINYLESTRADIOL; 7ALPHA METHYL NORETHISTERONE; ANDROGEN; ANDROSTENEDIONE; AROMATASE; CHLORMADINONE ACETATE; CONJUGATED ESTROGEN; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTRONE; ETHINYLESTRADIOL; MEDROXYPROGESTERONE ACETATE; NANDROLONE DERIVATIVE; NORETHISTERONE; NORETHISTERONE ACETATE; NORETYNODREL; ORAL CONTRACEPTIVE AGENT; STEROID; TESTOSTERONE; TIBOLONE; UNCLASSIFIED DRUG;

AROMATIZATION; BLEEDING; BREAST CANCER; CARDIOVASCULAR DISEASE; CATALYSIS; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG POTENCY; ENDOMETRIAL DISEASE; ENDOMETRIUM POLYP; GAS CHROMATOGRAPHY; HUMAN; LIVER; MASS SPECTROMETRY; MENOPAUSAL SYNDROME; OXIDATION; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; STROKE; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

ANDROGENS; AROMATASE; BREAST DISEASES; CARDIOVASCULAR DISEASES; ETHINYL ESTRADIOL; FEMALE; HUMANS; HYPERLIPOPROTEINEMIAS; LIVER; NANDROLONE; NORETHINDRONE; NORETHYNODREL; NORPREGNENES; UTERINE DISEASES;

EID: 34547157219     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130701380434     Document Type: Review

References (43)

1. Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 2005;8(Suppl 1):3-63
2. Wiegratz I, Sänger N, Kuhl H. Formation of 7α-methyl-ethinyl estradiol during treatment with tibolone. Menopause 2002;4:293-5
3. Davis SR, Simpson ER. Letter to the Editor. Kuhl H, Wiegratz I. In reply. Menopause 2003;10:105-7
4. Zacharia LC, Jackson EK, Kloosterboer HJ, Imthurn B, Dubey RK. Conversion of tibolone to 7a-methyl-ethinyl estradiol using gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry: interpretation and clinical implications. Menopause 2006;13:926-34
5. Timmer CJ, Verheul HAM, Doorstam DP. Pharmacokinetics of tibolone in early and late postmenopausal women. Br J Clin Pharmacol 2002;54:101-6
6. Kuhl H, Wiegratz I. Letter to the Editor. Menopause 2007;14:331-4
7. Brueggemeier RW, Hackett JC, Diaz-Cruz ES. Aromatase inhibitors in the treatment of breast cancer. Endocr Rev 2005;26:331-45
8. Simpson ER, Clyne C, Rubin G, et al. Aromatase - a brief overview. Annu Rev Physiol 2002;64:93-127
9. Vos RME, Krebbers SFM, Verhoeven CHJ, et al. The in vivo human metabolism of tibolone. Drug Metab Dispos 2002;30:106-12
10. Kuhnz W, Heuner A, Hümpel M, et al. In vivo conversion of norethisterone and norethisterone acetate to ethinyl estradiol in postmenopausal women. Contraception 1997;56:379-85
11. de Gooyer ME, Oppers-Tiemissen HM, Leysen D, et al. Tibolone is not converted by human aromatase to 7α-methyl-17α-ethynylestradiol (7α-MEE): analyses with sensitive bioassays for estrogens and androgens and with LC-MSMS. Steroids 2003;68:235-43
12. Raobaikady B, Parsons MFC, Reed MJ, et al. Lack of aromatization of the 3-keto-4-ene metabolite of tibolone to an estrogenic derivative. Steroids 2006;71:639-46
13. Yamamoto T, Yoshiji S, Yasuda J, et al. Aromatization of norethindrone to ethynylestradiol in human adult liver. Endocrinol Jpn 1986;33:527-31
14. Urabe M, Yamamoto T, Yoshiji S, et al. Aromatization of norethindrone to ethynylestradiol in human adult liver. Steroids 1987;50:607-8
15. Yamamoto T, Kitawaki J, Shiroshita K, et al. The confirmation of norethindrone aromatization in primary human hepatocytes by the vitafiber-II cell culture system. Acta Obstet Gynaec Jpn 1988;40:87-9
16. Reed MJ, Ross MS, Lai LC, et al. In vivo conversion of norethisterone to ethynyloestradiol in perimenopausal women. J Steroid Biochem Molec Biol 1990;37:301-3
17. Klehr-Bathmann I, Kuhl H. Formation of ethinylestradiol in postmenopausal women during continuous treatment with a combination of estradiol, estriol and norethisterone acetate. Maturitas 1995;21:245-50
18. Beier S, Düsterberg B, El Etreby MF, et al. Toxicology of hormonal fertility-regulating agents. In Benagiano G, Diczfalusy E, eds. Endocrine Mechanisms in Fertility Regulation. New York: Raven Press, 1983:261-346
19. Kloosterboer HJ. Tibolone and its metabolites: pharmacology, tissue specificity and effects in animal model of tumors. Gynecol Endocrinol 1997;11(Suppl 1):63-8
20. Thompson RM, Horning EC. Aromatization of the A-ring of norethynodrel, a steroidal oral contraceptive, during trimethylsilylation. Steroids Lipids Res 1973;4:135-42
21. Gomes MPV, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy. Arch Intern Med 2004;164:1965-76
22. Conard J, Plu-Bureau G, Bahi N, et al. Progestogen-only contraception in women at high risk of venous thromboembolism. Contraception 2004;70:437-41
23. Bodine PVN, Harris HA, Lyttle R, et al. Estrogenic effects of 7a-methyl-ethinylestradiol: a newly discovered tibolone metabolite. Steroids 2002;67:681-6
24. Cummings SR. LIFT study is discontinued. BMJ 2006;332:667
25. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA 2003;289:2673-84
26. Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005;365:1543-51
27. Kuhl H, Stevenson J. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits - an attempt to interpret the Women's Health Initiative results. Gynecol Endocrinol 2006;22:303-17
28. de Vries CS, Bromley SE, Thomas H, et al. Tibolone and endometrial cancer. A cohort and nested case-control study in the UK. Drug Safety 2005;28:241-9
29. Bjarnason NH. Endometrial cancer and hormone-replacement therapy. Lancet 2005;366:200-1
30. Whitehead MI, Townsend PT, Pryse-Davies J, et al. Effects of various types and dosages of progestogens on the postmenopausal endometrium. J Reprod Med 1982;27:539-48
31. Klaassens AHA, van Wijk FH, Hanifi-Moghaddam P, et al. Histological and immunohistochemical evaluation of postmenopausal endometrium after 3 weeks of treatment with tibolone, estrogen only, or estrogen plus progestogen. Fertil Steril 2006;86:352-61
32. Perez-Medina T, Bajo-Arenas J, Haya J, et al. Tibolone and risk of endometrial polyps: a prospective, comparative study with hormone therapy. Menopause 2003;10:534-7
33. Schoonen WGEJ, Deckers GH, de Gooijer ME, et al. Hormonal properties of norethisterone, 7α-methyl-norethisterone and their derivatives. J Steroid Biochem Mol Biol 2000;74:213-22
34. Dimitrakis C, Zhou J, Wang J, et al. A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause 2003;10:292-8
35. Dimitrakis C, Jones RA, Liu A, Bondy CA. Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy. Menopause 2004;11:531-5
36. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27
37. Stahlberg C, Tonnes Pedersen A, Lynge E, et al. Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Br J Cancer 2004;109:721-7
38. Farish E, Barnes JF, Fletcher CD, et al. Effects of tibolone on serum lipoprotein and apolipoprotein levels compared with a cyclic estrogen/progestogen regimen. Menopause 1999;6: 98-104
39. Milner M, Sinnott M, Gasparo D, et al. Climacteric symptoms, gonadotrophins, sex steroids, and binding proteins with conjugated equine estrogen-progestin and tibolone over two years. Menopause 1996;3:208-13
40. Larsson-Cohn U, Fahraeus L, Wallentin L, et al. Effects of the estrogenicity of levonorgestrel/ethinylestradiol combinations on the lipoprotein status. Acta Obstet Gynecol Scand Suppl 1982;105:37-40
41. Phillips A, Hahn DW, Klimek S, et al. A comparison of the potencies and activities of progestogens used in contraceptives. Contraception 1987;36:181-92
42. de Beer F, Smelt AHM, van Vark LC, et al. The effect of tibolone on the lipoprotein profile of postmenopausal women with type III hyperlipoproteinemia. J Intern Med 2002;251:148-55
43. Kushwaha RS, Hazzard WR, Gagne C, et al. Type III hyperlipoproteinemia: paradoxical hypolipidemic response to estrogen. Ann Intern Med 1977;87:517-25